Price to sales forward of Tactile Systems Technology, Inc. – HAM:3L3
This article displays the "Price to sales forward" value for Tactile Systems Technology, Inc. (HAM:3L3) on the Hamburg Stock Exchange. It indicates that the market was closed with no trades recorded for this specific financial metric. The content provided is primarily the header information for a financial data point.
Enterprise value to EBIT forward of Tactile Systems Technology, Inc. – NASDAQ:TCMD
This article provides an overview of the "Enterprise value to EBIT forward" metric for Tactile Systems Technology, Inc. (NASDAQ: TCMD) on TradingView. It briefly presents the company's stock information and financial data sections available on the platform, without offering specific financial figures or analysis in the provided content. The surrounding text outlines the various features and services offered by the TradingView platform.
Tactile Systems Technology, Inc.(NasdaqGM:TCMD) added to Russell 2500 Growth Benchmark
Tactile Systems Technology, Inc. (TCMD) has been added to the Russell 2500 Growth Benchmark, as well as several other Russell indices including the Russell Small Cap Comp Growth Benchmark and Russell 2000 Growth Benchmark, effective June 29, 2026. This news comes shortly after the company announced the full commercial launch of its next-generation Afflovest High-Frequency Chest Wall Oscillation Therapy System. The company's stock trades on NasdaqGM and focuses on medical devices for chronic diseases.
Tactile Systems Technology, Inc.(NasdaqGM:TCMD) added to Russell Small Cap Comp Growth Benchmark
Tactile Systems Technology, Inc. (NasdaqGM:TCMD) has been added to the Russell Small Cap Comp Growth Benchmark. This news, published on June 29, 2026, also indicates the company was simultaneously dropped from the Russell 2000 Defensive Index, Russell 2000 Value-Defensive Index, and added to several other Russell growth benchmarks. Tactile Systems Technology specializes in medical devices for chronic diseases like lymphedema and chronic respiratory conditions.
How Tactile Systems Technology Inc. (TCMD) Affects Rotational Strategy Timing
This article analyzes Tactile Systems Technology Inc. (TCMD) using AI models to determine its impact on rotational strategy timing. It highlights strong sentiment supporting an overweight bias, outlines institutional trading strategies (Position, Momentum Breakout, Risk Hedging), and provides multi-timeframe signal analysis with support and resistance levels.
Tactile Systems Technology, Inc.(NasdaqGM:TCMD) dropped from Russell 2000 Defensive Index
Tactile Systems Technology, Inc. (TCMD) has been removed from the Russell 2000 Defensive Index. Despite this change, the company was added to several other Russell indices including the Russell Small Cap Comp Growth, Russell 2500 Growth, Russell 2000 Growth, and Russell 3000E Growth Benchmarks. Tactile Medical, a medical technology company, specializes in at-home medical devices for chronic diseases.
Tactile Systems Technology, Inc.(NasdaqGM:TCMD) added to Russell 2000 Growth Benchmark
Tactile Systems Technology, Inc. (TCMD) has been added to the Russell 2000 Growth Benchmark. This news highlights the company's inclusion in a significant growth-oriented index, which often attracts increased investor attention. The article provides details about the company's profile, financial data, and recent news, including product launches and analyst rating changes.
How Tactile Systems Technology Inc. (TCMD) Affects Rotational Strategy Timing
The article analyzes Tactile Systems Technology Inc. (TCMD) using AI models, suggesting an overweight bias due to strong sentiment across all time horizons. It outlines three distinct trading strategies: a Long Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Short Strategy, each with specific entry, target, and stop-loss levels. The analysis also highlights strong support and resistance signals across near-term, mid-term, and long-term horizons for TCMD.
Tactile Systems Technology, Inc.(NasdaqGM:TCMD) added to Russell 3000E Growth Benchmark
Tactile Systems Technology, Inc. (NasdaqGM:TCMD) has been added to the Russell 3000E Growth Benchmark. This inclusion signifies the company's growth trajectory and could increase its visibility among investors. The medical technology company specializes in devices for chronic diseases like lymphedema and chronic respiratory conditions.
Selling US$1.6m Of Tactile Systems Technology Stock Rewarded Insiders
Insiders at Tactile Systems Technology sold US$1.6m worth of stock over the past year, with the largest sale by CEO Sheri Dodd for US$431k. Although the stock recently increased by 14%, these sales, especially below the current price, are seen as a cautious sign. While insiders still own 2.8% of the company, the consistent selling without corresponding purchases suggests a cautious outlook despite the company's profitability and growth.
Here's Why Tactile Systems Technology (NASDAQ:TCMD) Has Caught The Eye Of Investors
This article examines why Tactile Systems Technology (NASDAQ:TCMD) is attracting investor attention, focusing on its high return on capital employed (ROCE) and the significant reinvestment of earnings. The company's ability to generate impressive returns from its capital base and its strategic allocation of profits back into the business are highlighted as key factors driving its appeal. These aspects suggest a strong potential for sustained growth and value creation for shareholders.
Selling US$1.6m Of Tactile Systems Technology Stock Rewarded Insiders
Insiders at Tactile Systems Technology (NASDAQ:TCMD) sold shares worth US$1.6 million over the past year, with the CEO making the largest sale. This selling occurred even when the stock price was below its current value, which could signal potential weakness, despite recent share price gains. The article emphasizes that while insider selling is not definitively negative, it warrants caution, especially since there have been no insider purchases.
Tactile Systems Tech shares, weekly sector context for this medical device stock
Tactile Systems Tech (TCMD) is a U.S. medical device company specializing in home-based lymphedema therapy, operating within the broader medical equipment and supplies sector. The article provides a weekly context for the stock, highlighting its niche market, competitive landscape with larger medtech players, and the influence of analyst views on sector drivers and reimbursement policies. It also includes key company details and trading information for TCMD shares.
Tactile Systems Technology, Inc. Actuals & Estimates (NASDAQ:TCMD)
This article provides an overview of Tactile Systems Technology, Inc. (NASDAQ: TCMD) stock, including its current price, market capitalization, and historical performance. It details financial actuals and analyst estimates, future earnings dates, and revenue forecasts. The company's stock shows a "strong buy" rating according to technical analysis.
Tactile Systems Technology Inc (TCMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Tactile Systems Technology Inc (TCMD), focusing on its price momentum, support and resistance levels, and key technical indicators. The stock currently has a strong price momentum score and is trading within a range, making it suitable for swing trading. Technical indicators and moving averages largely suggest a 'Buy' signal for TCMD.
Tactile Systems Tech Stock - Long-term strategy and lymphedema focus
Tactile Systems Tech (TCMD) focuses on medical devices for treating lymphedema and chronic venous insufficiency, with no new market-moving news today steering the focus to its long-term strategy and business model. The company's revenue is primarily derived from device sales and services for home-based treatment, relying heavily on physician prescriptions, clinical evidence, and reimbursement coverage from U.S. Medicare and commercial insurers. Its growth is intrinsically linked to payer policies, coding decisions, and increased disease awareness among healthcare professionals.
(TCMD) and the Role of Price-Sensitive Allocations
This article analyzes Tactile Systems Technology Inc. (TCMD) through AI models, identifying a near-term neutral sentiment amidst mid and long-term strength. It highlights an exceptional risk-reward setup targeting a 22.9% gain with minimal risk, and outlines three distinct trading strategies: Position Trading, Momentum Breakout, and Risk Hedging. The analysis also provides multi-timeframe signal analysis with support and resistance levels.
Tactile Systems Technology Inc (TCMD) Institutional Confidence
Tactile Systems Technology Inc (TCMD) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. Institutional shareholding stands at 107.32%, a 5.59% increase quarter-over-quarter. James Simons is the largest institutional shareholder, holding 2.25% of outstanding shares.
Tactile Systems Technology Inc (TCMD) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Tactile Systems Technology Inc (TCMD), noting its current valuation score of 8.20 and its ranking within the Healthcare Equipment & Supplies industry. It highlights the company's P/E ratio relative to its recent high and low, while indicating that P/B, P/S, and P/CF data have not yet been disclosed by the company. The analysis is part of TradingKey's broader overview of the company's financial health, earnings forecast, price momentum, institutional confidence, and risk assessment.
Tactile Systems Technology Inc (TCMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution — TradingKey
This article provides a revenue breakdown for Tactile Systems Technology Inc (TCMD), detailing its performance by business segment. It shows that Lymphedema products account for 84.48% of revenue, while Airway clearance products contribute 15.52%. The report includes financial figures for FY2023, FY2024, and projected for FY2025.
Tactile Systems Technology Inc (TCMD) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides a detailed breakdown of Tactile Systems Technology Inc (TCMD) shareholder structure, listing major institutional holders and their proportion of shares. It also categorizes shareholder types and tracks institutional shareholding activity over several quarters. Key data points include the top institutional holders, their share percentages, and changes in their holdings.
Tactile Systems Technology Inc (TCMD) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for Tactile Systems Technology Inc (TCMD), highlighting its current earnings forecast score of 8.80, ranking 10th in the Healthcare Equipment & Supplies industry. Analysts have set an average price target of $24.00, with a consensus "Buy" rating based on 5 analysts. The company's expected revenue for the next quarter is $85.52 million, and the EPS forecast for the next quarter is $0.14.
Responsive Playbooks and the TCMD Inflection
This article provides an in-depth analysis of Tactile Systems Technology Inc. (NASDAQ: TCMD), highlighting strong sentiment across all time horizons and an exceptional 81.4:1 risk-reward setup. It details three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, offering specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy
Tactile Medical has launched its next-generation AffloVest high-frequency chest wall oscillation (HFCWO) therapy system, which includes enhancements designed to improve patient comfort, ease of use, and connected care capabilities. The new system is lighter, more adjustable, and features built-in Wi-Fi and Bluetooth connectivity, allowing patients to track progress and clinicians to access real-world data for personalized treatment. It maintains its indication for various chronic neuromuscular and respiratory conditions, aiming to improve therapy adherence and patient experience.
Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy
Tactile Medical has launched its next-generation AffloVest high-frequency chest wall oscillation (HFCWO) therapy system, designed to enhance patient comfort and adherence for those with chronic neuromuscular and respiratory conditions. The updated system features reduced weight, expanded size adjustability, and built-in Wi-Fi and Bluetooth connectivity for improved patient experience and data-driven clinical insights. This innovation aims to provide a more comfortable and connected therapy solution while maintaining clinical effectiveness.
New AffloVest makes home chest therapy lighter and connected for lung patients
Tactile Medical has launched its next-generation AffloVest, an airway clearance system designed for patients with chronic neuromuscular and respiratory conditions such as cystic fibrosis and bronchiectasis. The new device is lighter, more adjustable, and includes built-in Wi-Fi and Bluetooth for connected care, aiming to improve patient comfort, ease of use, and therapy adherence. These enhancements also provide clinicians and DME providers with real-world therapy data to support patient care and reimbursement.
Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy
Tactile Medical has launched its next-generation AffloVest high-frequency chest wall oscillation (HFCWO) therapy system, which is designed to improve patient comfort, ease of use, and connectivity. The new system is lighter, more adjustable, and includes built-in Wi-Fi and Bluetooth for tracking progress and sharing data with clinicians. It aims to enhance therapy adherence for individuals with chronic neuromuscular and respiratory conditions such as cystic fibrosis and bronchiectasis.
Tactile Medical Launches Next-Generation AffloVest® Airway Clearance Therapy
Tactile Medical has commercially launched its next-generation AffloVest high-frequency chest wall oscillation (HFCWO) therapy system, ahead of the winter respiratory season. This new system offers enhancements in patient comfort, ease of use, and connected care capabilities, including reduced weight, expanded size adjustability, and built-in Wi-Fi and Bluetooth. The AffloVest aims to improve therapy adherence and provide clinicians with real-world data to support personalized treatment for chronic respiratory conditions like cystic fibrosis and bronchiectasis.
Tactile Systems Technology Inc (TCMD) Stock Down 3.5% but Still Overvalued -- GF Score: 82/100
Tactile Systems Technology Inc (TCMD) shares dropped 3.5% to $24.61, yet GuruFocus assesses the stock as significantly overvalued with a current price 32.9% above its GF Value™ estimate of $18.52. Despite a strong GF Score™ of 82/100, driven by high financial strength and momentum, its valuation score is low, and recent insider selling further suggests caution for investors. The company's P/E ratio of 28.0x is 26% higher than its 5-year median, reinforcing the overvalued assessment.
TCMD Reiterated by BTIG -- Price Target Maintained at $40
BTIG has reiterated a "Buy" rating on Tactile Systems Tech (TCMD), maintaining a price target of $40.00, indicating strong analyst confidence despite the stock being identified as 34.7% overvalued by GuruFocus's GF Value™. TCMD boasts a high GF Score™ of 82/100, driven by strong financial strength and momentum, but its high P/E ratio and recent insider selling suggest investors should proceed with caution regarding its current valuation.
BTIG Research Reiterates Buy Rating for Tactile Systems Technology (NASDAQ:TCMD)
BTIG Research has reiterated a "Buy" rating for Tactile Systems Technology (NASDAQ:TCMD) and maintained a $40 price target, suggesting a potential 61% upside. Other analysts also have a "Moderate Buy" consensus with an average target of $38.60. The company recently reported mixed quarterly results, missing EPS estimates but exceeding revenue expectations, with shares trading around $24.84.
UBS Group AG Sells 168,372 Shares of Tactile Systems Technology, Inc. $TCMD
UBS Group AG significantly reduced its stake in Tactile Systems Technology ($TCMD) by selling 168,372 shares, ending with 197,715 shares valued at $5.7 million. Despite this, analyst sentiment remains positive with a "Moderate Buy" rating and a $38.60 average price target. The company also saw recent insider selling by its CEO and VP, missed EPS estimates, but exceeded revenue expectations in its latest quarter.
Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference
Tactile Medical announced that its management will participate in the William Blair 46th Annual Growth Stock Conference held in Chicago from June 2-4, 2026. The company's presentation is scheduled for June 2 at 9:20 a.m. Central Time, and a live audio webcast will be available on their investor relations website. An archive of the webcast will also be provided for replay after the conference.
Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference
Tactile Medical (Nasdaq: TCMD) announced its management will participate in the William Blair 46th Annual Growth Stock Conference from June 2-4, 2026, presenting on June 2nd at 9:20 a.m. Central Time. A live audio webcast will be available on the company's investor relations website. Tactile Medical is a medical technology company focused on at-home therapies for chronic conditions like lymphedema and chronic venous insufficiency.
Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference
Tactile Medical (Nasdaq: TCMD), a medical technology company, announced its participation in the William Blair 46th Annual Growth Stock Conference from June 2-4, 2026. Management will present on June 2nd, with a live audio webcast available on the company's investor relations website. The company focuses on developing at-home therapies for chronic conditions like lymphedema and chronic venous insufficiency.
Tactile Medical to webcast William Blair conference talk June 2
Tactile Medical (Nasdaq: TCMD) announced its management will present at the William Blair 46th Annual Growth Stock Conference in Chicago from June 2-4, 2026. The presentation is scheduled for Tuesday, June 2, at 9:20 a.m. CT, and a live audio webcast and replay will be available on the company’s investor relations website. Tactile Medical specializes in at-home therapies for chronic conditions such as lymphedema and lipedema.
Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference
Tactile Medical announced that its management will participate in the William Blair 46th Annual Growth Stock Conference, scheduled for June 2-4, 2026, in Chicago, IL. The company's presentation will take place on Tuesday, June 2, at 9:20 a.m. Central Time, with a live audio webcast and archived replay available on their investor relations website. Tactile Medical is a medical technology company specializing in at-home therapies for chronic conditions like lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease.
Tactile Systems Tech stock (US87874P1012): CFO sells $113K in shares
Tactile Systems Technology's CFO recently sold $113,403 worth of TCMD shares after the company reported stronger-than-expected Q1 earnings, with EPS of -$0.08 against an expected -$0.11 and revenue of $75.3 million. The medical device firm, which focuses on at-home therapies for chronic conditions like lymphedema, has seen its stock perform strongly, returning over 135% in the past year. Despite the insider sale, the company maintains a strong competitive position in the growing home healthcare market.
Tactile Systems CFO sells $113,403 in TCMD common stock
Tactile Systems Technology Inc.'s CFO, Elaine M. Birkemeyer, sold 4,631 shares of TCMD common stock for $113,403 on May 11, 2026, to cover taxes. Despite the insider sale, management has been actively buying back shares, showing confidence in the company. The company also reported strong Q1 2026 financial results, exceeding revenue and EPS expectations.
Tactile Systems CFO sells $113,403 in TCMD common stock
Tactile Systems Technology CFO Elaine M. Birkemeyer sold 4,631 shares of TCMD common stock for $113,403 to cover tax obligations, though management is actively buying back shares. The company recently reported strong Q1 2026 financial results, exceeding EPS and revenue expectations. The stock has seen a 138% return over the past year.
TCMD (NASDAQ: TCMD) affiliate lists 4,631 shares for resale; prior sales reported
An affiliate of Tactile Systems Technology Inc. (NASDAQ: TCMD) has filed a Form 144, listing 4,631 shares for proposed resale by Fidelity Brokerage Services LLC on May 11, 2026, stemming from restricted stock vesting on May 8, 2026. The filing also disclosed two prior sales by Elaine M. Birkemeyer: 5,518 shares sold on February 23, 2026, for $156,142.85, and 7,701 shares sold on February 24, 2026, for $222,874.64. This indicates ongoing selling activity by parties associated with the issuer.
Shareholders Will Be Pleased With The Quality of Tactile Systems Technology's (NASDAQ:TCMD) Earnings
Tactile Systems Technology (NASDAQ:TCMD) saw a positive stock price reaction following a strong earnings report. The analysis highlights that the company's statutory earnings likely understate its true potential, given its negative accrual ratio and free cash flow of US$39 million, significantly exceeding its US$20.3 million profit. Additionally, its earnings per share increased by 33% over the last year.
TACTILE SYSTEMS TECHNOLOGY (TCMD) director receives 6,521-share equity grant
TACTILE SYSTEMS TECHNOLOGY (TCMD) director Raymond Huggenberger received an equity grant of 6,521 restricted stock units, increasing his direct holdings to 62,841 shares. The grant, valued at $0.00 per share, vests fully on the earlier of one year from the grant date or the next annual stockholders' meeting, aligning his compensation with the company's long-term performance. This insider transaction was reported in an SEC Form 4 filing on May 8, 2026.
Tactile Systems Technology (TCMD) director awarded 6,521 RSUs
Tactile Systems Technology director William W. Burke was granted 6,521 restricted stock units (RSUs) of Common Stock, which will vest on the earlier of one year from the grant date or the next annual stockholders' meeting. This award increases his direct holdings to 55,041 shares. The transaction, reported on a Form 4 SEC filing, is categorized as a grant/award acquisition, not an open-market purchase, and is considered neutral in terms of filing sentiment and impact.
[Form 4] TACTILE SYSTEMS TECHNOLOGY INC Insider Trading Activity
Tactile Systems Technology director David Brent Shafer received an equity award of 6,521 restricted stock units, as detailed in a Form 4 SEC filing. These shares were granted at a price of $0.00 and will vest fully on the earlier of one year from the grant date or the next annual stockholders' meeting. After this transaction, Shafer directly holds 55,343 common shares in the company.
Carmen Volkart (TCMD) receives 6,521 restricted stock units as award
Carmen B. Volkart, a director at Tactile Systems Technology Inc. (TCMD), was granted 6,521 restricted stock units (RSUs) on May 6, 2026, as part of her compensation, with no purchase price. These RSUs will fully vest either one year from the grant date or by the next annual shareholders' meeting. Following this award, Ms. Volkart directly holds a total of 44,219 shares in the company.
[Form 4] TACTILE SYSTEMS TECHNOLOGY INC Insider Trading Activity
Tactile Systems Technology Inc. director Laura G. King received an equity award of 6,521 shares of Common Stock in the form of restricted stock units (RSUs) with a grant price of $0.00 per share. This non-cash compensation increases her direct holdings to 25,569 shares. The RSUs will vest in full on the earlier of one year from the grant date or the next annual stockholders' meeting, aligning her interests with continued board service.
[Form 4] TACTILE SYSTEMS TECHNOLOGY INC Insider Trading Activity
TACTILE SYSTEMS TECHNOLOGY INC director Valerie L. Asbury reported an acquisition of 6,521 shares of common stock as a restricted stock unit grant, which will vest on the earlier of one year from the grant date or the next annual meeting of stockholders. This transaction increases her direct holdings to 55,343 shares, with a grant price of $0.00 per share. The filing highlights key details of the grant and her subsequent ownership.
Tactile Systems Tech stock (US87874P1012): Q1 2026 sales up 23% on Medicare headwinds
Tactile Systems Technology (TCMD) reported a 23% year-over-year increase in Q1 2026 revenue, reaching $75.3 million, despite facing new Medicare prior-authorization requirements. The company's core business revolves around home-based compression therapy devices for chronic conditions, with its Flexitouch system being the primary revenue driver. While growth was attributed to strategic execution and commercial momentum, the stock remains volatile due to investor uncertainty regarding reimbursement policies and the sustainability of its turnaround.
Tactile Systems Technology, Inc. (NASDAQ:TCMD) Receives Consensus Rating of "Moderate Buy" from Analysts
Tactile Systems Technology, Inc. (NASDAQ:TCMD) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $38.60. Despite missing EPS estimates, the company exceeded revenue expectations in its latest quarter. Insider selling was observed, but institutional ownership remains high, with several major funds increasing or establishing positions.
